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Abstract 16 
The crotonases comprise a widely-distributed enzyme superfamily that has multiple 17 
roles in both primary and secondary metabolism. Many crotonases employ oxyanion hole-18 
mediated stabilization of intermediates to catalyze the reaction of coenzyme A (CoA) 19 
thioester substrates (e.g., malonyl-CoA, α,β-unsaturated CoA esters) with both nucleophiles 20 
and, in the case of enolate intermediates, with varied electrophiles. Reactions of crotonases 21 
that proceed via a stabilized oxyanion intermediate include the hydrolysis of substrates 22 
including proteins, as well as hydration, isomerization, nucleophilic aromatic substitution, 23 
Claisen-type, and cofactor-independent oxidation reactions. The crotonases have a conserved 24 
fold formed from a central β-sheet core surrounded by α-helices, which typically 25 
oligomerizes to form a trimer, or dimer of trimers. The presence of a common structural 26 
platform and mechanisms involving intermediates with diverse reactivity implies that 27 
crotonases have considerable potential for biocatalysis and synthetic biology, as supported by 28 
pioneering protein engineering studies on them. In this Perspective article, we give an 29 
overview of crotonase diversity and structural biology, then illustrate the scope of crotonase 30 
catalysis and potential for biocatalysis. 31 
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Introduction 37 
Enzymes belonging to the widely distributed crotonase superfamily catalyze a very 38 
broad spectrum of reactions (Figure 1). The crotonases have multiple important and highly 39 
conserved metabolic roles in both eukaryotes and prokaryotes, as exemplified by the 40 
prototypical crotonases, enoyl-CoA hydratase (ECH) and enoyl-CoA isomerase (ECI), which 41 
are crucially involved in the b-oxidation pathway of fatty acid metabolism.1 The term 42 
‘crotonase’ has been used to refer specifically to ECH,1 but it is used in this Perspective to 43 
refer to the entirety of the superfamily of enzymes bearing the crotonase-type fold. 44 
Crotonases are also involved in the biosynthesis of biomedicinally important secondary 45 
metabolites, including the carbapenem and glycopeptide antibiotics, and in microbial 46 
catabolic pathways associated with the degradation of amino acids, peptides, and pollutants, 47 
including chlorinated compounds (for previous reviews see Hamed et al.2 and Holden et al.3). 48 
Many of the reactions catalyzed by crotonases are analogous to well-established 49 
reactions proceeding via enol/enolate intermediates that are commonly used in the synthesis 50 
and functionalization of carbonyl compounds in synthetic organic chemistry. Such reactions 51 
include aldol and retro-aldol condensations, decarboxylations, hydrations and isomerizations 52 
of unsaturated carbonyl compounds, and amide hydrolysis (Figure 1). Some crotonase 53 
catalyzed reactions are beyond the routine scope of routine synthetic methodology, such as 54 
the efficient cofactor-free oxidation of a substrate as mediated by dioxygen4 and the one step 55 
synthesis of functionalized heterocycles.5 Coenzyme-A (CoA) thioester derivatives are the 56 
most common crotonase substrates, though many crotonase fold enzymes employ other 57 
substrate types, notably including proteins (Figure 1).2,3 58 
The crotonase superfamily has >120,000 proposed members, according to the 59 
InterPro database (family ID IPR001753).6 As indicated by sequence similarity network 60 
analyses, enzymes belonging to the crotonase superfamily are ubiquitous in all life forms and 61 
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manifest substantial sequence diversity (Figure 2, S1, Table S1). These analyses further 62 
suggest that, as a group, the crotonase enzymes remain largely understudied (Figure S1), and 63 
it is likely that the chemical diversity attributed to enzymes belonging to this superfamily will 64 
continue to expand. 65 
Crystallographic studies reveal that, despite often low overall sequence homology 66 
(Figure 2), all crotonases manifest a conserved overall fold comprising repeated bba 67 
subunits, which form a scaffold of major and minor b-sheets in a roughly perpendicular 68 
arrangement, surrounded by a-helices (Figure 3A, 3B).2,3,7 By way of example, views from 69 
crystal structures of the crotonase CarB reveal a major b-sheet comprised of six b-strands and 70 
a minor b-sheet of three b-strands (Figure 3B).8 Most crotonase enzymes tend to oligomerize 71 
as trimers or dimers of trimers in solution (and in crystals) (Figure 3C), although some adopt 72 
other oligomerization states; the C-terminal a-helical region is usually important in 73 
oligomerization.2 74 
Crystal structures of substrate or product complexes to crotonases reveal a conserved 75 
horseshoe-like conformation for the bound CoA element, with the adenyl group oriented in 76 
close proximity to the phosphopantetheinyl part and the thioester located near to/within the 77 
active site (Figure 3D). The substrate binding pocket is typically made up of the minor b-78 
sheet and the neighbouring loops and a-helices. The active site of each crotonase monomer is 79 
located near the interface of two adjacent monomers, and may consist in part of residues from 80 
the C-terminal a-helices of a neighbouring monomer.9 81 
As might be anticipated from their conserved fold and active sites, many reactions 82 
catalyzed by crotonases have common mechanistic elements (Figure 1A). In particular, most 83 
crotonase reactions involve activation of a carbonyl group by binding of the carbonyl oxygen 84 
in an oxyanion hole, wherein hydrogen bonds with protein backbone amide groups polarize 85 
and increase the electrophilicity of the substrate (often, but not always, a thioester) carbonyl 86 
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carbon. Binding in the oxyanion hole can not only enable direct nucleophilic addition onto 87 
the carbonyl group, but can also promote reactions involving an enolate intermediate, as 88 
exemplified by the different types of crotonase reactions summarized in Figure 1A. The key 89 
role of the oxyanion hole in crotonase catalysis is analogous to that of the oxyanion hole in 90 
the catalysis of the serine/cysteine proteases and other hydrolytic enzymes, such as the N-91 
terminal nucleophilic hydrolases; indeed some crotonase superfamily members act as 92 
proteases, e.g., the bacterial caseinolytic and Tricorn proteases.10 93 
Due to their ability to catalyze diverse reactions in a stereo- and regioselective manner 94 
using structurally related substrates and a common protein scaffold, the engineering of 95 
crotonase enzymes into robust biocatalysts holds considerable, as yet largely untapped, 96 
promise. Pioneering work has hinted at this potential, including applications for the 97 
production of biofuels;11 the bioproduction of n-butanol has been engineered in bacteria via a 98 
metabolic pathway involving a crotonase.12 Crotonase enzymes are also candidates for 99 
engineering studies aiming to produce (intermediates of) bioactive molecules, including 100 
pharmaceuticals and other high value chemicals, as well as chiral starting materials, as 101 
exemplified in substrate analogue studies with 6-oxocamphor hydrolase (6-OCH).13–15 Of 102 
particular note from a commercial perspective has been the development of recombinant 103 
organisms which use bacterial enoyl-CoA hydratase/aldolase, a crotonase enzyme, coupled 104 
with a CoA-synthetase for conversion of ferulic acid to a ‘natural’ form of the expensive 105 
flavor vanillin (Figure 4).16–18 More recently, a hydratase/lyase (VpVAN) catalyzing the 106 
conversion of ferulic acid itself into vanillin has been reported.19 However, VpVAN shows 107 
higher sequence similarity to the cysteine proteases than the crotonases, and its role in 108 
vanillin synthesis has been subsequently questioned.20 109 
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In this Perspective, we illustrate the diverse scope of crotonase catalysis by describing 110 
the reactions catalyzed by and mechanisms proposed for six mechanistically diverse 111 
crotonases (Figure 1B). These enzymes represent distinct members of the crotonase structural 112 
superfamily, and have relatively low sequence similarity (Figure 2). We begin with a 113 
description of ECH and ECI, which catalyze relatively simple double bond hydration and 114 
isomerization reactions, but which have central roles in fatty acid b-oxidation; ECH and ECI 115 
were amongst the first crotonases to be characterized.1 The ring-forming menaquinone 116 
biosynthetic enzyme MenB is discussed, with focus on its potential as an antibiotic target.9 117 
We then describe crotonases involved in the biosynthesis of the clinically important b-lactam 118 
and glycopeptide antibiotics. Recent substrate analysis and engineering work on CarB 119 
(carboxymethylproline synthase B), which catalyzes the committed step in carbapenem 120 
biosynthesis,5 exemplifies the potential of crotonases for the stereoselective synthesis of 121 
heterocycles. DpgC (3,5-dihydroxyphenylacetyl-CoA 1,2-dioxygenase) is a chemically 122 
interesting cofactor-independent oxygenase that synthesizes precursors for glycopeptide 123 
antibiotic assembly.21 4-Chlorobenzoyl-CoA dehalogenase (4-CBD) is involved in the 124 
biodegradation of chlorinated aromatic compounds.22 Finally, 6-oxocamphor hydrolase (6-125 
OCH), which is involved in the bacterial degradation of camphor, is discussed with an 126 
emphasis on its ability to desymmetrize achiral substrates and provide enantioenriched 127 
products for synthetic chemistry.14 We hope that this article will promote further studies on 128 
the biocatalytic potential of existing and new members of the crotonase superfamily. 129 
 130 
ECH/ECI - Enoyl-CoA Hydratase/Enoyl-CoA Isomerase 131 
The β-oxidation fatty acid pathway involves the catabolic transformation of long 132 
chain fatty acids into acetyl-CoA. ECH catalyzes the second step of the β-oxidation pathway, 133 
i.e., the syn-addition of a water molecule across the double bond of an α,β-unsaturated enoyl-134 
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CoA thioester substrate (e.g., crotonyl- or methacrylyl-CoA, Figure 5A).7,23 ECH displays 135 
activity towards unsaturated CoA thioesters with different chain lengths, although the 136 
turnover rate decreases for longer substrates.24 137 
Crystallographic studies reveal that the ECH structure adopts a functional hexamer 138 
comprising two stacked trimers.7 The CoA moiety of the substrate adopts the typical 139 
horseshoe conformation in a binding pocket formed from two adjacent monomers, while the 140 
active site catalytic residues are provided by a single monomer (Figure 5C). The active site of 141 
rat liver mitochondrial ECH contains an oxyanion hole formed from the backbone amides of 142 
Gly141 and Ala98, which serves to polarize the carbonyl group of the a,b-unsaturated enoyl-143 
CoA substrate and stabilize the enolate intermediate. Two active site glutamate residues 144 
(Glu144 and Glu164) are proposed to act as a general base(s) for the conjugate addition of 145 
water onto the substrate enone, and to protonate the resultant enolate (Figure 5A, 5C). 146 
Introduction of two glutamate residues into the active site of 4-CBD (see below) in positions 147 
corresponding to these residues in ECH provided a 4-CBD variant with a hydratase activity 148 
not seen with wild-type 4-CBD,25 highlighting the potential of rationally engineering 149 
crotonase enzymes. 150 
Catalysis by ECI, which is closely related to ECH, enables fatty acids with double 151 
bonds not conjugated to the thioester/carboxylate carbonyl to enter the β-oxidation catabolic 152 
pathway (Figure 5B). Glu165 in ECI (numbering based on the rat liver mitochondrial 153 
enzyme), which is analogous to Glu164 in ECH, is essential for proton relay between C2 and 154 
C4 to form the corresponding 2E-enoyl-CoA.26–28 As with ECH, two backbone amide protons 155 
form an oxyanion hole which activates the thioester carbonyl of the 3E- or 3Z-enoyl-CoA 156 
substrate. Crystallographic analyses of human ECI type 2 (or HsECI2) indicates that the C-157 
terminal a-helix-10 is involved in substrate binding, and in combination with loop-2 and 158 
loop-4, in orienting the substrate for catalysis.29 Studies on the binding of substrate analogues 159 
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to the yeast peroxisomal ECI imply extensive hydrogen bond networks involving the catalytic 160 
glutamate residue (Glu165) and the residues making up the oxyanion hole.30 161 
Some enzymes (e.g., rat peroxisomal multifunctional enzyme, type 1) have both ECH 162 
and ECI activities; these enzymes employ an active site with two glutamate residues.28,31 163 
Through the use of an additional domain, some multifunctional crotonase enzymes can also 164 
catalyze a further step in fatty acid catabolism, i.e., the oxidation of the enoyl-CoA hydratase 165 
product.28 166 
Substituting Lys242 with a non-basic residue in rat liver mitochondrial ECI resulted 167 
in a mutant protein with ECH activity.32 Furthermore, rat mitochondrial ECH-1 (which has 168 
the two glutamate residues typical of ECH) has isomerase activity, albeit much lower than its 169 
hydratase activity.33 While mutation of Glu144 to alanine in this enzyme diminished the 170 
isomerase activity by 10-fold, mutation of Glu164 to alanine decreased the isomerase activity 171 
1000-fold; the hydratase activity was decreased 2000-fold for both mutants.33 While the 172 
hydratase activity depends on both glutamate residues, the isomerase activity (as with 173 
dedicated ECI enzymes) relies mostly on a single glutamate. The catalysis of more than one 174 
reaction by a single active site, in combination with the observation that residue substitutions 175 
can be used to alter reaction pathways, highlights the potential of crotonase-fold enzymes as 176 
scaffolds amenable to engineering to elicit new activities. 177 
 178 
MenB – 1,4-Dihydroxy-2-naphthoyl-CoA Synthase 179 
Menaquinone has an essential role in the electron transport chain in many bacteria.34 180 
Enzymes involved in menaquinone biosynthesis are potential antibiotic targets, including the 181 
crotonase MenB (or 1,4-dihydroxy-2-naphthoyl-CoA synthase). MenB catalyzes the 182 
intramolecular Claisen condensation of O-succinylbenzoyl-CoA to form the naphthyl core of 183 
menaquinone (Figure 6A). The MenB mechanism is proposed to proceed via the concerted 184 
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protonation of the substrate carboxylate, thereby increasing its electrophilicity, and 185 
deprotonation of the α-position of the CoA thioester (Figure 6A).35 The resultant thioester 186 
enolate is then proposed to undergo an intramolecular addition-elimination reaction with the 187 
carboxylic acid of the intermediate; subsequent enolization of the two keto groups yields the 188 
1,4-dihydroxy-2-naphthoyl-CoA product. 189 
Crystallographic studies reveal that MenB exists as a dimer of trimers in the 190 
crystalline state, as also observed in solution.9,36,37 The MenB active site is primarily 191 
composed of residues from a single monomer, with some residues contributed from the C-192 
terminal a-helices of an adjacent subunit.37 Differences in the active site are observed in the 193 
complex of MenB with product analogues, suggesting substantial conformational changes 194 
during catalysis.38,39 A co-crystal structure of Escherichia coli MenB with a substrate 195 
analogue reveal details of MenB catalysis (Figure 6B),35 such as the formation of an 196 
oxyanion hole from the backbone amides of Gly86 and Gly133 which activates the substrate 197 
to promote deprotonation at the α-position. The side chains of Tyr97 and Tyr258¢ (from an 198 
adjacent subunit) activate the substrate carboxylic acid by protonation to promote the 199 
intramolecular addition-elimination reaction of the CoA enolate.35 200 
Crystal structures of MenB from different bacterial species suggest mechanistic 201 
variations (Figure 6B), including in the identity of the base responsible for generating the 202 
thioester enolate.35 Interestingly, the activity of E. coli MenB is dependent on bicarbonate, as 203 
supported by crystallographic evidence which revealed a bicarbonate ion near the active site 204 
(Figure 6C).40,41 The dependence, or not, of catalysis on bicarbonate has been used to 205 
categorize types of MenB enzymes; structural analyses of some type I MenB enzymes 206 
manifest a bicarbonate ion bound next to an active site glycine residue, while type II enzymes 207 
(e.g., from Mycobacterium tuberculosis)36 contain an aspartate residue in place of the glycine 208 
and do not show bicarbonate dependence (Figure 6C, 6D). Because the aspartate residue of 209 
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the type II enzymes is proposed to be the general base responsible for substrate thioenolate 210 
formation, the bicarbonate-dependence of the type I enzymes has led to the proposal that 211 
bicarbonate acts as the base41 (however, crystallographic analyses of some type I enzymes do 212 
not show bound bicarbonate).35 It has also been proposed that the substrate itself may act as a 213 
base during catalysis.35 Based on a crystal structure of E. coli MenB with a bound substrate 214 
mimic, one oxygen of the substrate C7 carboxylate is likely < 3 Å away from the pro-2S 215 
proton.35 Further, the corresponding C7 methyl ester is not a substrate, despite binding tightly 216 
to MenB,35 consistent with involvement of the substrate C7 carboxylate in intramolecular 217 
proton transfer. 218 
High-throughput screening for inhibitors of MenB from M. tuberculosis led to the 219 
identification of compounds with a 2-amino-4-oxo-4-phenylbutanoate scaffold.42 However, 220 
such compounds were found to only inhibit MenB following a pre-incubation step, requiring 221 
a non-enzymatic elimination to form 4-oxo-4-phenylbut-2-enoate. Furthermore, addition of 222 
CoA to the reaction mixture greatly improved the extent of inhibition, resulting from the 223 
Michael addition of free CoA onto the a,b-unsaturated enone of the inhibitor (Figure 6E). 224 
Modeling studies suggest that these inhibitors may exploit structural features common to 225 
crotonases. In addition to the expected favourable binding of the inhibitor CoA moiety, the 226 
inhibitor carboxylate group is likely positioned in the oxyanion hole. Beyond MenB, such 227 
(precursors of) CoA-based inhibitors may represent a general approach to the inhibition of 228 
crotonase superfamily enzymes. 229 
 230 
CarB - Carboxymethylproline Synthase 231 
Crotonases play key roles in the biosynthesis of the medicinally important 232 
carbapenem antibacterials.43 It has not yet been possible to develop fermentation routes to 233 
produce clinically useful carbapenems or precursors thereof; hence, unlike most other β-234 
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lactam antibacterials, carbapenems are produced by total synthesis, with consequent cost of 235 
goods issues. There is thus interest in engineering carbapenem biosynthesis to improve 236 
production of existing clinically important carbapenems and to produce new b-lactam 237 
antibacterials. Unexpectedly, this work has heralded the potential of crotonase engineering 238 
for stereoselective control of enolate reactivity. 239 
Three enzymes (CarA, B, C) are directly involved in the biosynthesis of the simplest 240 
carbapenem, (5R)-carbapenem-3-carboxylic acid (Figure 7A).44 CarB, a crotonase 241 
superfamily enzyme from Pectobacterium carotovorum, catalyses the first step, i.e., the 242 
reaction of (2S)-pyrroline-5-carboxylic acid (P5C) and malonyl-CoA to give the β-amino acid 243 
(2S,5S)-carboxymethyl proline (t-CMP). t-CMP then undergoes CarA-catalyzed and ATP-244 
dependent bicyclic β-lactam ring formation to give (2S,5S)-carbapenam-3-carboxylic acid. 245 
The 2-oxoglutarate dependent oxygenase CarC then catalyzes epimerization at C-5 and 246 
desaturation to give (5R)-carbapenem-3-carboxylic acid. ThnE, from Streptomyces cattleya, 247 
is proposed to play an analogous role to that of CarB in the biosynthesis of more complex 248 
carbapenems such as thienamycin. The (5R)-stereochemistry is required for carbapenem 249 
antibacterial activity; the reason for the apparently ‘wasteful’ epimerization at the beginning 250 
of this route is unknown.2,45 251 
CarB has the conserved crotonase fold as revealed by crystallography, and is trimeric 252 
in solution.8 CarB/ThnE catalysis is proposed to proceed via decarboxylation of malonyl-253 
CoA to give an enolate (Figure 7B), which is stabilized by the conserved oxyanion hole. The 254 
enolate then likely reacts with the iminium form of P5C (in solution, P5C is in equilibrium 255 
with 5-hydroxyproline and glutamate semi-aldehyde) to form an enzyme-bound thioester 256 
intermediate, which undergoes hydrolysis, most likely via direct reaction with a glutamate 257 
(Glu131 in CarB) activated ‘hydrolytic’ water molecule.46 258 
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Studies on the substrate and product selectivities of wildtype and engineered variants 259 
of CarB and ThnE illustrate the potential of crotonases for stereocontrolled biocatalysis 260 
involving enolate intermediates (Figure 7C, D, E).47–51 Although considerable work would be 261 
required to develop these unnatural CarB/ThnE reactions to commercial utility (likely using 262 
cell-based biosynthesis, in part due to the cost of making isolated malonyl-CoA derivatives), 263 
this work reveals the potential of crotonases for the highly stereocontrolled synthesis of 264 
functionalized heterocycles of pharmaceutical interest. 265 
 CarB has an apparently strict requirement for malonyl-CoA derivatives and the (S)-266 
stereochemistry of pyrroline-5-carboxylate, but in other regards its selectivity is relaxed. 267 
Wild type CarB and active site variants can catalyze formation of 6- and 7-membered ring β-268 
amino acid products from the appropriate aldehydes/imines (Figure 7C).47 CarB/ThnE 269 
variants can produce products methylated at all the carbons of the product proline ring, 270 
including the sterically demanding quaternary C-2 and C-5 positions (Figure 7D).49 271 
There is even more flexibility in terms of the malonyl-CoA derivatives accepted, and 272 
several straight and branched malonyl-CoA derivatives can be converted (Figure 7E).48 The 273 
stereoselective catalysis of CarB variants can be coupled to the enzyme-catalyzed synthesis 274 
of malonyl-CoA derivatives by malonyl-CoA synthetase, or, in more limited cases, using 275 
crotonyl-CoA carboxylase reductase (Ccr) from crotonyl- or acryloyl-CoA.50 276 
Di- or tri-alkylated CMP derivatives can also be synthesised using combinations of 277 
malonyl-CoA and P5C derivatives.47,49,52 In many cases, the β-amino acid products of CarB 278 
catalysis have been converted into bicyclic β-lactams by CarA, which catalyzes the step after 279 
CarB in carbapenem biosynthesis (Figure 7A).47,52 Such dual-enzyme catalysis has enabled 280 
the efficient production of multiple bicyclic β-lactams which would otherwise be challenging 281 
to efficiently synthesize via non-enzymatic methodology.47 282 
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The standout feature revealed by the substrate analogue and engineering work with 283 
CarB/ThnE is the potential for stereoselective control in crotonase catalysis. In the case of the 284 
conversion of the malonyl-CoA derivatives to give C-6 alkylated CMP derivatives, 285 
stereocontrol substantially depends on the selective generation and reaction of the appropriate 286 
trisubstituted (E)- or (Z)-enolate intermediate. Active site variants of CarB/ThnE, including at 287 
the oxyanion stabilizing site, have enabled production of C-6 methylated and ethylated 288 
derivatives of t-CMP with very high stereoselectivities for either the (6S)- or (6R)-products. 289 
In some cases, stereoselectivity can be enhanced by coupling (engineered) CarB/ThnE 290 
asymmetric catalysis with production of the C-2 alkylated malonyl-CoA derivatives using 291 
malonyl-CoA synthetase or Ccr.48,50 292 
In the case of C-2 alkylated malonyl-CoA CarB substrates, the C-2 position 293 
undergoes epimerization under the assay incubation conditions. In cases where the rate of 294 
epimerization limits the stereoselectivity inherent in CarB catalysis, a malonyl-CoA 295 
epimerase can be added to improve stereoselectivity, including when using Ccr to prepare the 296 
malonyl-CoA derivative in a one pot three enzyme synthesis of C-5 ethylated t-CMP starting 297 
from crotonyl-CoA and CO2.51 298 
 299 
DpgC 300 
Some of the most mechanistically interesting crotonase enzymes act as cofactor-301 
independent oxygenases.53 DpgC, a hexameric crotonase superfamily oxygenase produced by 302 
actinomycetes, is involved in the biosynthesis of 3,5-dihydroxyphenylgycine, a precursor to 303 
the glycopeptide antibiotics. DpgC catalyzes the dioxygen-dependent, but cofactor-304 
independent, four-electron oxidation of 3,5-dihydroxyphenylacetyl-CoA (DPA-CoA) to give 305 
3,5-dihydroxyphenylglyoxylate (DPGX) (Figure 8A).4,21 DPGX is then converted to an 306 
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amino acid, as catalyzed by the transaminase HpgT, and incorporated into glycopeptide 307 
antibiotics (such as vancomycin and teicoplanin) by non-ribosomal peptide synthetases. 308 
Crystallographic studies have examined the cofactor-independent nature of DpgC 309 
catalysis and identified a putative hydrophobic dioxygen-binding pocket near the substrate 310 
binding site (Figure 8B).54–56 Mutations to the proposed dioxygen-binding pocket decreased 311 
the catalytic efficiency and raised the apparent KM for oxygen.57 Biophysical, modelling and 312 
mutagenesis studies indicate that dioxygen can follow different pathways to the active site, 313 
where it is concentrated in a position suitable for reaction with the substrate.58 314 
While the DpgC reaction is unusual among crotonases, its proposed mechanism 315 
manifests features typical of the superfamily (Figure 8A).54 Deprotonation of the a-position 316 
to the thioester carbonyl is proposed to be catalyzed by a water molecule, with the resultant 317 
enolate stabilized by an oxyanion hole formed by the backbone amides of Gly296 and Ile235. 318 
Electron transfer from the substrate enolate to the bound oxygen molecule is proposed to 319 
form a substrate radical cation and superoxide anion pair, which undergo reaction to give a 320 
peroxide. The distal oxygen of this peroxide may then react with the thioester carbonyl, again 321 
facilitated by the oxyanion hole (Figure 8A). The resultant dioxetanone intermediate can then 322 
undergo elimination to give the DPGX product. 323 
 324 
4-CBD - 4-Chlorobenzoyl-CoA Dehalogenase 325 
4-CBD catalyzes the hydrolytic dehalogenation of 4-chlorobenzoyl-CoA, forming 4-326 
hydroxybenzoyl-CoA. Bacteria producing 4-CBD include Pseudomonas sp. CBS3 (or 327 
Burkholderia sp. CBS3),22 Arthrobacter sp. 4-CB1,59 Betaproteobacteria,60 and Arthrobacter 328 
sp. TM-1.61 4-CBD is also able to hydrolyze other 4-substituted benzoyl-CoA substrates, 329 
including 4-fluoro-, 4-bromo-, 4-iodo-, and 4-nitrobenzoyl-CoA, suggesting scope for 330 
engineering work.62,63 Crystallographic studies on 4-CBD from Burkholderia sp. CBS3 reveal 331 
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it oligomerizes to form a trimer with the participation of the C-terminal a-helices from one 332 
monomer in the active site of another, as observed with other crotonases, e.g., MenB (Figure 333 
6B).22,35 334 
The 4-CBD catalytic mechanism has been investigated experimentally and 335 
computationally (Figure 9A). The rate-determining step is proposed to be the nucleophilic 336 
addition of a carboxylate oxygen of Asp145 onto the C4 position of 4-chlorobenzoyl-CoA to 337 
form an enzyme-Meisenheimer complex (EMc) intermediate, as supported by QM/MM 338 
studies and Raman spectroscopy.62,64,65 The backbone amide protons of Phe64 and Gly114 339 
form an oxyanion hole (Figure 9B), which polarizes the substrate thioester carbonyl so 340 
increasing the electrophilicity of the substrate aromatic ring.66,67 His90 is thought to increase 341 
the nucleophilicity of Asp145,68,69 while Trp137 and Glu232 are proposed to orient Asp145 342 
towards the substrate.70,71 The EMc intermediate rearomatizes with loss of chloride, which is 343 
displaced into a pocket initially proposed to be formed by Phe64, Phe82, and Trp89,69 344 
although computational studies suggest the chloride receiving pocket may be formed from 345 
Ala86, His90, and Ile223¢.64 Rearomatization of the EMc results in an aryl-enzyme ester 346 
intermediate, which is then hydrolyzed (with His90 acting as a general base) to yield 4-347 
hydroxybenzoyl-CoA.69 Product release is proposed to proceed by a conformational change 348 
and ion shuffle, resulting in the extrusion of a proton and a chloride ion from the active site. 349 
 350 
6-OCH - 6-Oxocamphor Hydrolase 351 
6-OCH catalyzes the hydrolysis of the diketone 6-oxocamphor, giving a ~6:1 mixture 352 
of (2R,4S)- and (2S,4S)-α-campholinic acid (Figure 10A; note that a similar ratio of cis- and 353 
trans-isomers as a racemate was observed for the corresponding acid-catalyzed hydrolysis).14 354 
A crystal structure of 6-OCH from Rhodococcus sp. NCIMB 9784 has the typical hexameric 355 
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crotonase-type fold (Figure 10B), with the C-terminal a-helix of one monomer folding back 356 
over the core to cover the active site of the same monomer.72 357 
Unusually for the crotonase superfamily, the 6-OCH substrate lacks a CoA thioester. 358 
Furthermore, a structure of the H122A variant of 6-OCH with bound product (2S,4S)-α-359 
campholinic acid suggests that 6-OCH does not contain the typical crotonase oxyanion hole 360 
composed of backbone amide protons; instead the substrate enolate is likely stabilized by the 361 
side chains of Trp40 and His122.73 362 
His145 is proposed to act as a general base in 6-OCH catalysis, catalyzing the 363 
addition of water to the pro-(S) face of symmetrical 6-oxocamphors (Figure 10A).72 The 364 
resulting tetrahedral oxyanion can then undergo a retro-Claisen reaction, forming a 365 
carboxylic acid and enolate. While Trp40 and His122 likely stabilize the enolate 366 
intermediate, they may also limit the nucleophilic addition of water onto the ketone with 367 
which they interact.73 The enolate may then be protonated on either face; protonation on the 368 
pro-(R) face is favored, resulting in a 6:1 mixture of (2R,4S)- and (2S,4S)-α-campholinic acid. 369 
6-OCH can generate optically active products from achiral symmetrical substrates 370 
(Figure 10C), and is tolerant to a range of common organic solvents.74 Furthermore, the 371 
activity and stereoselectivity of 6-OCH are preserved at temperatures up to 50 °C. As a 372 
consequence, 6-OCH has seen application for the asymmetric synthesis of substituted 373 
cyclopentanones and cyclohexanones from symmetrical bridged bicyclic 1,3-diketones.13,14 In 374 
a one pot cascade process involving three enzymes, which nicely exemplifies how ‘natural’ 375 
enzymes can be combined for the efficient synthesis of unnatural asymmetric compounds 376 
from achiral precursors, the products of 6-OCH catalysis were sequentially modified by 377 
lipase catalyzed ester formation followed by transaminase catalyzed amine formation to give 378 
d-amino esters.75 379 
	 17	
 Various monocyclic ring systems have also been shown to be 6-OCH substrates. 380 
Simple 2,2-disubstituted-1,3-cyclohexadiones were converted by 6-OCH to give 1,5-keto 381 
acids, although only a racemic mixture of products was obtained from these substrates.13,14 382 
Fused 5,6 and 5,7 rings with non-enolisable 1,3-diketone systems also displayed reactivity 383 
with 6-OCH, producing enantioenriched products.15 384 
Limitations to the substrates accepted by 6-OCH remain, with all substrates thus far 385 
identified containing a cyclic 1,3-diketone scaffold. In addition, substrates require a non-386 
enolizable centre between the two ketones, thereby excluding many simpler 1,3-diketones.15 387 
However, the impact of active site residues on the substrate scope of 6-OCH has yet to be 388 
fully characterized and these enzymes are interesting targets for engineering to introduce new 389 
activities. 390 
 391 
Conclusions and Future Perspectives 392 
The examples in this Perspective illustrate the catalytic versatility of the crotonase 393 
superfamily in terms of both substrate and reaction selectivity. The available structural and 394 
mechanistic evidence suggests that the versatility of the crotonases arises substantially from 395 
their ability to efficiently form, stabilize, and control the reactivity of oxyanion intermediates, 396 
often in the form of enolates. The oxyanion is stabilized by conserved hydrogen bonds in the 397 
oxyanion hole, and general acid/base catalysis is commonly mediated by aspartate, glutamate, 398 
and histidine residues.76 Although, oxyanion hole-type carbonyl activation is supported by 399 
other protein folds, it is possible that the crotonase fold is particularly good at supporting a 400 
diverse set of reactions/substrates – this hypothesis could be investigated by systematic 401 
designed studies employing both natural and unnatural folds. Many of the crotonase 402 
catalyzed reactions described here (Figure 1B) are analogous to reactions involving carbonyl 403 
compounds routinely used in organic synthesis. One obvious advantage of the enzymatic 404 
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transformations is stereocontrol. The stereoelectronic and mechanistic insights generated by 405 
studies on crotonases and related enzymes employing oxyanion intermediates76 are providing 406 
inspiration for the development of non-protein based catalysts; pioneering work suggests 407 
there is considerable scope for the generation of powerful asymmetric catalysts.77 408 
It is important to appreciate that the extent of crotonase catalysis extends well beyond 409 
the examples highlighted in this Perspective. As supported by bioinformatic analyses (Figure 410 
S1, Table S1), the full scope of crotonase catalysis has not yet been realized, and many 411 
members of this superfamily are understudied. Furthermore, several structurally ‘atypical’ 412 
crotonases are known that catalyze biologically important reactions. Interestingly, the 413 
majority of the atypical crotonases retain most of the characteristic elements of the conserved 414 
monomeric crotonase fold, but do not necessarily trimerize in the same manner as the more 415 
typical crotonases. Amongst the atypical members are the crotonase-fold serine proteases 416 
such as Clp, which is an antibacterial drug target,78 and the biotin-dependent 417 
carboxylases/carboxyltransferases. A crystal structure of bacterial ClpP, the proteolytic 418 
domain of the caseinolytic protease Clp, reveals a crotonase-type fold distinct from the major 419 
families of serine proteases (Figure 11A).79 In spite of its different fold, the key catalytic 420 
residues of ClpP required for proteolysis are positioned similarly as in other classes of serine 421 
proteases (e.g., subtilisin), in an apparent example of convergent evolution (Figure 11B). 422 
Such convergence is supported by subsequently solved structures of further serine proteases 423 
with a crotonase-type fold (e.g., photosystem II D1 C-terminal processing protease, tricorn 424 
protease).80,81 Another biologically interesting atypical crotonase is acetyl-CoA carboxylase 425 
(ACC), which is involved in the regulation of fatty acid metabolism.82 This enzyme catalyzes 426 
carboxylation of acetyl-CoA to give malonyl-CoA, which is a substrate for other crotonases. 427 
The enolate of acetyl-CoA, stabilized by an oxyanion hole, is positioned by ACC to react 428 
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with a covalently bound carboxybiotin molecule, which is generated through the action of a 429 
biotin carboxylase domain.83 430 
The conservation of key catalytic features in both typical and atypical crotonases, 431 
coupled to the range of reactions catalyzed by the crotonases, suggests that there is 432 
considerable scope for engineering them, both in terms of tweaking the selectivity of the 433 
existing reactions they catalyze and to develop new reactions. In contrast to the oxyanion 434 
hole, CoA binding, and general acid/base machinery, there appears to be much more variation 435 
in the specific substrate binding pockets of crotonases. The results of the limited protein 436 
engineering and synthetic biology work carried out on the crotonases, such as with 6-OCH,75 437 
the carboxymethylproline synthases,50 and vanillin production,84 suggest that they may be 438 
amenable to the development of biocatalysts of industrial utility. 439 
Although not a limitation for all crotonases (e.g., 6-OCH),13 in the case of the CoA-440 
employing crotonases, most short term industrial applications of crotonase catalysis are likely 441 
to be in cells due to the current high cost of CoA thioesters. The pantetheine group of the 442 
CoA present in typical crotonase substrates binds in a conserved and relatively rigid manner 443 
in a tunnel leading to the enzyme active site (Figure 3D), acting as a handle to locate the 444 
reactive elements of the intermediate at the active site. One productive line of future 445 
investigation could be to engineer crotonases that do not require CoA thioesters, but which 446 
catalyze the diverse reaction types presently catalyzed by crotonases using either truncated 447 
CoA thioesters, or preferably, simple acids/esters/amides. Given the range of electrophiles 448 
naturally accepted for reaction with enolates by crotonases, including gases such as dioxygen 449 
and carbon dioxide, and the proven utility of reactions of non-enzyme derived enolates with 450 
electrophiles, engineering crotonase-bound enolate intermediates to react with unnatural 451 
electrophiles is of particular interest. 452 
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To date, protein engineering on crotonases has been guided by structural knowledge 453 
gained from crystallography (>85 crystal structures deposited by mid 2017 in the PDB; Table 454 
S1), which has provided information on active sites that has informed on stereoelectronic 455 
details of catalysis76 and been used to alter catalytic properties of crotonases.32,50 The 456 
oliogomeric nature of most crotonases and the conformational changes that likely occur 457 
during catalysis (probably underestimated by crystallographic studies) means that knowledge 458 
of solution structures of crotonases, in particular in complex with substrates, will be 459 
informative with respect to future engineering efforts. Such knowledge may take some time 460 
to emerge, and given that the interactions between monomers are, at least sometimes, 461 
involved in catalysis, it may be non-trivial to apply towards the design of new catalysts. 462 
Hence, semi-rational approaches to altering crotonase catalysed reactions, employing directed 463 
evolution type methods are of interest,85 as is the potential design of consensus, possibly 464 
monomeric, crotonases for use as templates on which to engineer tailored active sites. 465 
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Figure Legends 638 
Figure 1. Reactions catalyzed by crotonase superfamily enzymes (crotonases). (A) 639 
Crotonases catalyze a diverse range of reactions, most commonly with substrates activated as 640 
coenzyme A (CoA) thioesters (highlighted in purple). These reactions tend to involve the 641 
stabilization of an enolate (or tetrahedral alkoxide) intermediate via an oxyanion hole 642 
(orange). (B) Scheme showing the reactions catalyzed by crotonase enzymes highlighted in 643 
this Perspective. 644 
Figure 2. Representative sequence similarity network86 for the crotonase superfamily, 645 
colored by the domains of life, and displaying the distribution of the enzymes discussed 646 
in the Perspective (indicated with large red nodes). Each node represents a set of protein 647 
sequences that are >65% identical (total number of nodes = 16916). Edges linking nodes are 648 
drawn if the identity between a pair of nodes is better than a Blast E value of 1x10-40. The 649 
total number of proteins with a crotonase fold is estimated to be ~122,924 according to the 650 
InterPro database (Family ID IPR001753).6 The figure was generated using the EFI web 651 
tool87 (minimum alignment score = 50) and Cytoscape 3.5.1 software.88 The network reveals 652 
the relative size of clusters of nodes (of likely functionally related enzymes); note the 653 
ECH/ECI cluster is the largest. 654 
Figure 3. Typical structural features of crotonase enzymes. (A) Topology of a CarB 655 
monomer, displaying the repeated ββα motif. Residues involved in the highly, but not 656 
universally, conserved oxyanion hole are indicated with asterisks. β-Strands are indicated in 657 
yellow, while α-helices are in blue, or green for the C-terminal α-helix. (B) View from a 658 
crystal structure of a CarB monomer from Pectobacterium carotovorum, with bound acetyl-659 
CoA (represented as yellow sticks; PDB 2A81). (C) The trimeric oligomerization state of 660 
CarB (PDB 2A7K); note the role of the C-terminal a-helices α6, α7, and α10 in 661 
oligomerisation. (D) The horseshoe-like conformation of acetyl-CoA bound to CarB (PDB 662 
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2A81); inset shows the chemical structure of a generic CoA thioester. Note that electron 663 
density was not observed for the full CoA substrate in this structure, as indicated with the 664 
black line. This unresolved part of the substrate extends through a tunnel towards the active 665 
site. 666 
Figure 4. Involvement of a crotonase in vanillin production. Reaction scheme showing the 667 
formation of vanillin from ferulic acid in Streptomyces sp. strain V-1. Scheme adapted from 668 
Yang et al.17 The intermediate shown in square brackets was not observed. 669 
Figure 5. ECH/ECI mechanism and structural features. (A) Proposed outline mechanism 670 
of ECH catalysis (numbering according to the rat liver mitochondrial enzyme). (B) Proposed 671 
outline mechanism of ECI catalysis (numbering according to the rat liver mitochondrial 672 
enzyme). (C) View from rat liver mitochondrial ECH active site showing key residues 673 
interacting with substrate analogue acetoacetyl-CoA (PDB 1DUB).7 Dotted lines represent 674 
hydrogen bonds between the substrate thioester carbonyl oxygen and the backbone amide 675 
protons of Ala98 and Gly141. Glu144 and Glu164 are indicated in the same colors as in panel 676 
A. 677 
Figure 6. MenB mechanism and structural features. (A) Proposed mechanism of MenB 678 
catalysis. (B) View from the Escherichia coli MenB active site with bound substrate mimic 679 
O-succinylbenzoyl-aminoCoA (OSB-NCoA), using dotted lines to represent hydrogen bonds, 680 
the two oxyanion holes formed from Gly86 and Gly133, and from Tyr97 and Tyr258¢ (PDB 681 
3T88).35 Note that Tyr258' belongs to an adjacent monomer of EcMenB. (C) View from the 682 
E. coli MenB active site showing a bound bicarbonate ion (PDB 4ELS).41 In some cases a 683 
bicarbonate ion may provide general acid base catalysis.41 (D) View from the Mycobacterium 684 
tuberculosis MenB active site showing bound product analogue 1-hydroxy-2-naphthoyl-CoA 685 
(1-HNA-CoA) and putative basic residue Asp185 (PDB 4QIJ).39 The hydrogen bonds 686 
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between the product thioester carbonyl oxygen and the backbone amide protons of Gly105 687 
and Gly161 are represented as dotted lines. The putative general base Asp185 is shown. (E) 688 
Scheme showing the non-enzymatic generation of CoA-based inhibitor adducts from 2-689 
amino-4-oxo-4-phenylbutanoates.42 690 
Figure 7. Role of carboxymethylproline synthases in carbapenem biosynthesis. (A) 691 
Biosynthesis of the simplest carbapenem as catalyzed by the crotonase CarB, the synthetase 692 
CarA, and the oxygenase CarC. (B) Proposed outline mechanism of CarB catalysis. (C) 693 
Capacity of CarB and variants to catalyse the formation of different ring sizes (5- to 7-694 
membered N-heterocycles). (D, E) Biocatalytic production of unnatural carbapenams by 695 
engineered CarB/CarA sequential catalysis, employing alkylated substrate analogues 696 
(including those generated via tandem catalysis by MatB/Ccr in panel E). 697 
Figure 8. Catalytic and structural features of DpgC. (A) Proposed mechanism of DpgC 698 
catalysis. (B) View of a crystal structure of DpgC from Streptomyces toyocaensis with bound 699 
substrate analogue DPA-NH-CoA, showing dioxygen bound in a hydrophobic pocket (PDB 700 
2NP9).54 Note that the residues thought to make up the hydrophobic pocket are shown as dark 701 
blue sticks. The hydrogen bonds between the substrate analogue carbonyl oxygen and the 702 
backbone amide protons of Ile235 and Gly296 are represented by dotted lines. 703 
Figure 9. Mechanistic and structural features of 4-CBD. (A) Proposed outline mechanism 704 
of 4-CBD catalysis. (B) View from crystal structure of the Burkholderia sp. CBS3 4-CBD 705 
active site showing a bound molecule of 4-chlorobenzoylacetyl-CoA (4-CBA-CoA) (PDB 706 
1NZY).22 Hydrogen bonds between the substrate thioester oxygen and the backbone amide 707 
protons of Phe64 and Gly114 are represented as dotted lines. The nucleophilic Asp145 708 
residue involved in formation of the Meisenheimer complex is shown as sticks. 709 
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Figure 10. Mechanistic, structural and biocatalytic features of 6-OCH. (A) Proposed 710 
outline mechanism of 6-OCH catalysis. (B) View from a crystal structure of the Rhodococcus 711 
sp. NCIMB 9784 6-OCH H122A variant with bound product α-campholinic acid (PDB 712 
1SZO).73 Note that the oxyanion hole is proposed to be formed by the side chains of Trp40 713 
and His122 (mutated to alanine in this structure). The hydrogen bond between the 714 
substrate/product carbonyl and the indole side-chain of Trp40 is represented by a dotted line. 715 
The proposed general base, His145, is shown in a stick representation. (C) Substrate scope of 716 
6-OCH, showing conversion of monocyclic and bicyclic non-enolizable 1,3-diketones. 717 
Figure 11. Comparison of serine protease active sites. (A) View from a crystal structure of 718 
the Escherichia coli crotonase-fold serine protease, ClpP (PDB 1TYF).79 Ser97 acts as a 719 
nucleophile, as assisted by the general base His122, while the backbone amide protons of 720 
Gly68 and Met98 form an oxyanion hole. (B) View from a crystal structure of the serine 721 
protease subtilisin from Bacillus amyloliquefaciens (PDB 1ST2).89 Ser221 acts as a 722 
nucleophile, while His64 acts as a general base; the oxyanion hole is composed of the 723 
backbone amide proton of Ser221 and the side-chain of Asn155. 724 
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